Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This World Cancer Day, we heard from four Group Leaders at the MRC Weatherall Institute of Molecular Medicine about their work and how their groups are helping in the fight against cancer.

Professor KJ Patel is the Chief Scientist of Cancer Research UK, as well as the Director of both the MRC WIMM and the MRC Molecular Haematology Unit (MRC MHU). The Patel Group are investigating how alcohol can contribute to the emergence of a number of common cancers.

Andi Roy is a Professor of Paediatric Haematology in the Department of Paediatrics and a member of the MRC MHU. She is also an honorary paediatric haematology consultant at Great Ormond Street Hospital in London. Professor Roy leads her group in the study of childhood leukaemia, specifically blood cancers, and how they develop early in life.

Ahmed Ahmed is a Professor of Gynaecological Oncology in the Nuffield Department of Women’s Reproductive Health and a consultant surgeon at the Oxford Cancer and Haematology Centre. The Ahmed Group is looking into how normal cells develop into cancer cells, with the aim of improving early detection of ovarian cancers. 

Ben Fairfax is a Professor of Cancer Immunogenetics in the Department of Oncology, in addition to being an honorary consultant oncologist with the Oxford University Hospitals. His group researches how genetics can influence how well patients respond to cancer immunotherapy. 

 

This video highlights just some of the amazing research being carried out by MRC WIMM researchers in this field. 

See the full story on the WIMM website.

The research mentioned in this video was funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust, Ovarian Cancer Action and the NIHR Oxford Biomedical Research Centre.

Similar stories

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Study reveals blood stem cells can ‘remember’ inflammation

Researchers have discovered that some human blood stem cells retain a lasting “memory” of inflammation, a finding that could help explain links between ageing, chronic disease, and blood cancers

Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb (BMS), and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

New study reveals how blood cell production responds to parasite infection

Research led by the Nerlov Group in the MRC Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.

Oxford research highlights the global challenge of iron deficiency

Iron deficiency affects more than a billion people worldwide and remains a leading cause of anaemia. Oxford researchers are uncovering how iron levels shape immunity and infection - insights that could inform safer, more effective strategies to tackle iron deficiency globally.

Similar stories

New personalised therapy targets chronic blood cancer

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to a new study led by UCL and University of Oxford researchers.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Study reveals blood stem cells can ‘remember’ inflammation

Researchers have discovered that some human blood stem cells retain a lasting “memory” of inflammation, a finding that could help explain links between ageing, chronic disease, and blood cancers

Reversing T cell exhaustion improves effectiveness of myeloma immunotherapies

Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb (BMS), and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against multiple myeloma.

New study reveals how blood cell production responds to parasite infection

Research led by the Nerlov Group in the MRC Molecular Haematology Unit provides the first detailed explanation of how parasite-fighting immune cells are selectively increased following infection.

Oxford research highlights the global challenge of iron deficiency

Iron deficiency affects more than a billion people worldwide and remains a leading cause of anaemia. Oxford researchers are uncovering how iron levels shape immunity and infection - insights that could inform safer, more effective strategies to tackle iron deficiency globally.